Bone WizardryMEDICAL EDUCATION
⌘ KStart free
Back
On this page
0%
Skip to lesson

pharm

Gabapentinoids: Target, Exposure and Clinical Decisions

Connect gabapentinoid target binding with absorption, renal clearance, condition-specific evidence and safety decisions, then apply the distinctions to clinical cases.

How can gabapentin and pregabalin share a binding target but still require different treatment decisions? Follow three questions: what changes at the nerve terminal, how much drug reaches the circulation, and how quickly it leaves. You should be able to explain why a plausible mechanism does not establish benefit for every pain syndrome, and why predictable absorption does not remove the need to assess kidney function and tolerability.

A binding target is not the same as a complete mechanism

When an action potential reaches a presynaptic terminal, voltage-gated calcium entry helps trigger vesicle fusion and transmitter release. Changing the number or availability of channels can therefore change evoked calcium entry and release. Experimental gabapentinoid effects on channel trafficking or current connect to that relationship; they do not by themselves establish the size or timing of a human analgesic response. LYRICA mechanism evidence Evoked-release experiment

Start with the location. Gabapentinoids bind an auxiliary alpha-2-delta subunit associated with voltage-gated calcium channels. The name does not make them direct GABA-receptor agonists. Both product labels also state that the full relationship between their molecular actions and clinical benefit is not completely established. Keep that qualification beside the mechanism rather than removing the mechanism from the lesson. Gabapentin label, section 12.1 Pregabalin label, section 12.1

Now separate a channel's presence at the membrane from its opening. In cell systems and sensory neurons, sustained gabapentin exposure reduced surface channel expression and calcium currents under specific experimental conditions. Binding-disrupting mutations prevented that drug effect. The finding supports a trafficking mechanism; it is not an image of a drug instantly plugging every channel pore. Hendrich and colleagues: trafficking experiments

A related animal experiment adds spatial context. After spinal nerve injury in rats, alpha-2-delta-1 increased along the sensory pathway. Pregabalin treatment reduced its elevation in presynaptic spinal terminals without removing the increase in the sensory-neuron cell bodies. Production and delivery are different steps. This model does not measure how much a particular person's pain will improve. Bauer and colleagues: nerve-injury model

What would preserved protein in the cell body, but less at the terminal, help you distinguish?

It distinguishes reduced delivery to the terminal from simply stopping production. The location of the change matters to the explanation.

Apply that distinction to a new experiment: unchanged basal transmitter levels do not rule out an effect on release evoked by stimulation. Rodent slice experiments measured those outcomes separately. A treatment effect depends on the preparation, the stimulus and the measured outcome. Quintero and colleagues: stimulus-evoked glutamate release

Separate the fraction absorbed from the amount absorbed

Gabapentin's absorbed fraction falls as its dose rises. Pregabalin's oral bioavailability is at least 90 percent and remains dose-independent across its studied range. These facts concern exposure, not a guarantee of greater benefit or equal milligram doses. Gabapentin pharmacokinetics, section 12.3 Pregabalin pharmacokinetics, section 12.3

Use an abstract example before interpreting a drug chart. If 60 percent of 100 units is absorbed, 60 units enter the body. If 40 percent of 200 units is absorbed, 80 units enter. The fraction fell, but the amount increased. These invented units illustrate the arithmetic; they are not observed gabapentin data or a dosing instruction.

Does a falling absorbed fraction mean that increasing the dose has no effect on exposure?

No. Multiply the dose by the absorbed fraction before comparing the amount absorbed. Do not infer a complete ceiling merely from a declining percentage.

Predictable absorption also does not mean that pregabalin should always begin at its final dose. Its label adjusts escalation to response, tolerability and indication. Renal function adds another decision. Keep absorption, dose selection and clinical response as separate questions. Pregabalin administration and dosing, section 2

High, predictable bioavailability does not prove passive diffusion. Experiments in rat intestine and Caco-2 cells found different transport behavior; those preparations do not justify declaring one exclusive human absorption route from a percentage alone. Food can delay pregabalin peak concentration without meaningfully changing total absorption. Rate, fraction and amount are different measurements. Experimental transport study LYRICA absorption

Aluminum-magnesium antacids can reduce immediate-release gabapentin absorption. Its label recommends taking gabapentin at least two hours after such an antacid. A reduced input and reduced renal clearance can oppose each other, but their net effect is not predictable without knowing their magnitudes. NEURONTIN antacid interaction

The same input can persist longer when clearance falls

Absorption describes entry; clearance describes removal. In a single-dose study of people with different renal function, lower creatinine clearance was associated with higher pregabalin exposure and a longer elimination half-life. Hemodialysis was studied separately. This supports renal adjustment, not a single dose that fits every indication or dialysis schedule. Randinitis and colleagues: renal pharmacokinetics

Consider a teaching example in which the prescribed dose stays constant while renal function declines. The original prescription is unchanged, but the conditions controlling exposure are not. Ask whether the medicine, its indication, the relevant renal estimate and other sedating medicines still fit together before attributing new drowsiness only to the underlying illness.

Would more predictable absorption protect this patient from slower elimination?

No. Predictable entry does not guarantee predictable removal when renal function changes.

The product tables use creatinine clearance, commonly estimated by Cockcroft-Gault in stable renal function. An automatically reported body-surface-area-indexed eGFR is not the same quantity in every patient, and rapidly changing renal function needs clinical judgment rather than false precision from a stable-state formula. Establish the product, indication and current renal assessment before choosing a table entry. NEURONTIN renal assessment LYRICA renal assessment

For illustration, the LYRICA renal table maps normal-function totals of 150, 300, 450 and 600 mg/day to 75, 150, 225 and 300 mg/day at CrCl 30-60 mL/min. Select the intended indication-specific reference first. Hemodialysis can then introduce a separate removal event and supplemental-dose instruction; a supplement does not universally replace maintenance. These instructions differ across products. LYRICA renal and dialysis table HORIZANT indication-specific renal instructions

In a simplified single-dose model, each elimination half-life halves the remaining amount. Starting with 100 units, a six-hour half-life leaves 25 units after twelve hours; a twelve-hour half-life leaves 50. With repeated input, more residue can remain before the next dose. This teaches persistence, not a patient-specific concentration or dosing schedule.

A controlled IV reference can separate absorption from removal in a pharmacokinetic experiment. With equal oral and IV doses and linear elimination, bioavailability equals oral AUC divided by IV AUC, while clearance equals IV dose divided by IV AUC. If the doses differ, compare dose-normalized exposures instead. The IV/oral exercises here are constructed models, not a route or dose recommendation for a patient. Gabapentin absorption and elimination Pregabalin absorption and elimination

Match the evidence to the condition and the product

A binding target explains a possible action; an indication identifies where a particular product has supporting regulatory evidence. Neither is a promise that a patient will benefit. In the United States, immediate-release NEURONTIN is labeled for postherpetic neuralgia in adults and adjunctive treatment of focal seizures from age three. LYRICA covers diabetic peripheral neuropathic pain, postherpetic neuralgia, fibromyalgia, spinal-cord-injury neuropathic pain and adjunctive focal-seizure treatment from one month of age. Those age limits concern the seizure indications, not every pain condition. NEURONTIN indications LYRICA indications

Off-label is not synonymous with ineffective. Gabapentin has supporting evidence and a guideline role in painful diabetic polyneuropathy despite lacking that US label indication. Conversely, having neuropathic features does not make every pain syndrome respond like diabetic neuropathy. Generalized anxiety disorder is an indication for pregabalin in the European Union, not a US LYRICA indication. State the jurisdiction instead of mixing regulatory lists. AAN painful diabetic polyneuropathy guideline European Medicines Agency Lyrica information

Connect the indication to the exposure ceiling. In adults with normal renal function, the US LYRICA label recommends no more than 300 mg/day for diabetic peripheral neuropathic pain and 450 mg/day for fibromyalgia. For postherpetic neuralgia, higher dosing may be considered only after an adequate trial at 300 mg/day with persistent pain and acceptable tolerability. A 600 mg/day ceiling elsewhere in the label is not permission to use that dose for every indication. Renal adjustment comes after choosing the indication-appropriate reference regimen. LYRICA dosing by indication

Formulation is part of the prescription. Immediate-release gabapentin, gastroretentive GRALISE and the gabapentin-enacarbil prodrug HORIZANT have different administration and indication instructions; equal numbers of milligrams do not establish interchangeability. HORIZANT has a US restless-legs indication, which should not be assigned to every gabapentin product. Do not substitute a familiar formulation's food instructions or dosing frequency for the dispensed product's label. GRALISE product distinction HORIZANT product distinction

Which question comes first: the renal-table row or the indication-specific regimen?

Determine the product and intended indication-specific regimen first, then map it to the renal-function row. A row contains several possible totals because renal function is not the only input.

Interpret a changed patient, not just an unchanged prescription

Sleepiness, dizziness and impaired coordination connect drug exposure to daily function. Ask about falls, driving, work and other sedating medicines; a numerically acceptable dose can still be poorly tolerated. Peripheral edema, weight gain and blurred vision are additional reasons to reassess. Avoid treating an adverse-effect frequency from one trial as a universal probability across all doses and indications. Pregabalin-associated edema deserves particular care with thiazolidinediones and in patients with heart-failure concerns. NEURONTIN adverse effects LYRICA adverse effects

Respiratory risk is not the same as ordinary drowsiness. Opioids or other central nervous system depressants, underlying respiratory impairment and older age can increase the risk of serious breathing problems. Reduced renal clearance can add accumulation. Someone who is difficult to wake with slow or shallow breathing needs urgent assessment and ventilatory support as indicated, not simply a slower future titration. Naloxone addresses an opioid contribution when present; it is not an antidote to gabapentin or pregabalin. FDA breathing-risk warning Gabapentin overdose and interactions Pregabalin overdose

A planned discontinuation differs from an emergency reaction. Both labels advise gradual reduction over at least one week when stopping, with a longer individualized course when needed. That minimum is not a guarantee against withdrawal. Anxiety, insomnia, sweating, nausea and other symptoms can follow interruption; recurrence of the treated disease and other acute illness remain alternatives. A patient with confusion after missed doses needs assessment rather than an automatic unsupervised return to the previous dose. Seizure risk also matters when a drug is being used for epilepsy. NEURONTIN discontinuation LYRICA discontinuation

Possible anaphylaxis, angioedema or a serious multisystem hypersensitivity reaction changes the priority: stop the suspected drug and obtain urgent care according to the presentation. Do not continue a suspected culprit solely to satisfy a routine taper rule. Fever, lymph-node enlargement and organ injury can require investigation even before a rash appears. New suicidal thoughts similarly require direct safety assessment rather than waiting for a scheduled medication review. Serious gabapentin warnings Serious pregabalin warnings

Physical dependence after regular exposure is not by itself a diagnosis of a substance use disorder. Ask directly and respectfully about dose use, benefits, problems and co-exposures. A substance-use history informs risk assessment; it does not prove the cause of a new symptom or exclude a genuine pain condition. Dependence and reported misuse Abuse and dependence distinctions

Why can the response to new drowsiness differ from the response to new tongue swelling?

Drowsiness calls for a severity, exposure and co-medication assessment. Tongue swelling may signal an airway-threatening reaction, where urgent care and stopping the suspected drug take priority.

Concrete reasons to assess medication use further include taking additional or nonprescribed doses, escalating outside the agreed plan, or combining the drug with other depressants. Ask what happened and assess safety rather than treating a request by drug name, tolerance or withdrawal alone as proof of a substance use disorder. Physiologic adaptation, return of the original condition and problematic use can require different responses. Gabapentin misuse and dependence information Pregabalin misuse and dependence information

Judge benefit with a patient outcome, not a plausible story

Define the pain condition and a useful goal before choosing treatment. Burning pain in a distal symmetric neuropathy, persistent pain after shingles and radiating pain from a nerve root are not interchangeable study populations. Ask what the patient hopes to do more comfortably, such as sleep, walk or work, and reassess both symptom change and adverse effects. Reducing a pain score while creating falls may not be a useful trade. Mood, sleep and other contributors deserve attention alongside the medicine. AAN assessment and treatment principles

Two trials show why within-person improvement is not enough to establish a drug effect. In a 12-week randomized gabapentin trial for chronic low back pain, both treatment and placebo groups improved, but the between-group comparison did not support a gabapentin benefit. In PRECISE, pregabalin did not improve sciatica leg pain over placebo at eight weeks, and more adverse events were reported with pregabalin. These findings constrain use for those studied conditions; they do not erase separate evidence for postherpetic neuralgia or diabetic polyneuropathy. Atkinson trial PRECISE trial

When reading an outcome estimate, first identify its direction and unit. A difference of zero is the null value for a difference in pain scores. One is the null value for a risk ratio. A confidence interval containing the null does not prove exact equivalence. Also distinguish the number of adverse events from the number of people with an event: one participant can experience more than one event. These distinctions determine what a trial can actually support. PRECISE outcome definitions and results

For painful diabetic polyneuropathy, the AAN guideline includes gabapentinoids, SNRIs, tricyclic antidepressants and sodium-channel blockers as effective medication classes, with patient factors considered beyond efficacy. If an initial class provides no meaningful improvement or causes significant adverse effects, offer a trial from another effective class. This is not an instruction to stop abruptly, combine drugs indiscriminately or assume a second gabapentinoid solves a class-related problem. Non-drug care and management of the underlying condition continue. AAN recommendations

A patient improved during treatment, but an appropriate placebo group improved similarly. What remains unproved?

The improvement alone does not establish that the medicine caused it. Compare between-group outcomes and uncertainty, then decide whether the studied population matches the clinical question.

Use the same sequence at follow-up: identify the current condition, check the exact product and exposure determinants, compare benefit with harm, and agree on the next step. The binding target starts the explanation; it does not finish the clinical decision.

Patient-specific constraints can separate otherwise relevant choices. Duloxetine has US indications for diabetic neuropathic pain, fibromyalgia and adult GAD, but its label advises avoiding it in chronic liver disease or cirrhosis. TCAs are another effective neuropathy class, yet prior serious urinary retention weighs against re-exposure to an atropine-like medicine such as amitriptyline. Venlafaxine extended release has an adult GAD indication but not a fibromyalgia indication. These distinctions support a choice; none establishes universal superiority. AAN class guidance CYMBALTA indications and precautions Amitriptyline precautions EFFEXOR XR indications

For a defined harm over a specified interval, number needed to harm is the reciprocal of the absolute increase in the proportion of affected patients. Event totals cannot supply that proportion when one person can have several events. For a trial planning comparison, keep the chosen effect threshold separate from zero: PRECISE used a1.5-point between-group pain difference in its planning. That target should not be presented as a universally validated threshold for every patient. PRECISE results PRECISE analysis plan

Independent clinical practice

Use the supplied findings to choose the best answer. Explanations and optional reasoning are available locally; requesting help does not require a guess.

Case 1

A learner sees the name gabapentin on a prescription for postherpetic neuralgia and assumes it directly activates a GABA receptor. Which molecular target should replace that assumption?

Show answer and explanations for case 1

  1. A. An auxiliary alpha-2-delta calcium-channel subunit (Best answer)

    Gabapentin binds an auxiliary alpha-2-delta subunit associated with voltage-gated calcium channels. The relationship between all molecular effects and clinical benefit remains incompletely established.

  2. B. The GABA-A receptor chloride-channel complex (Why this does not fit)

    Gabapentin was developed as a structural analogue of GABA. Structural similarity does not establish direct GABA-A receptor activation.

  3. C. The GABA-B receptor signaling complex (Why this does not fit)

    It would describe a receptor-agonist mechanism rather than alpha-2-delta binding. Gabapentin is not a direct GABA-B receptor agonist.

  4. D. The benzodiazepine binding site on GABA-A receptors (Why this does not fit)

    Several drugs can cause sedation through different molecular targets. Use demonstrated binding rather than a shared adverse effect.

Takeaway: The drug name and sedation do not identify its binding site.

Case sources: [1] [2]

Case 2

For the stated absorption calculation, dose A contains 100 units with 60 percent absorbed. Dose B contains 200 units with 40 percent absorbed. How does the amount absorbed change?

Show answer and explanations for case 2

  1. A. It falls from 60 to 40 units (Why this does not fit)

    Forty percent is a fraction, not forty absorbed units. Multiply each dose by its own absorbed fraction.

  2. B. It rises from 60 to 80 units (Best answer)

    Two hundred multiplied by 0.40 is eighty units. A declining fraction can coexist with a larger total amount absorbed.

  3. C. It doubles from 60 to 120 units (Why this does not fit)

    The absorbed fraction decreased between the two doses. The larger dose is multiplied by a smaller fraction.

  4. D. It stays at 60 units (Why this does not fit)

    The second product of dose and fraction would also have to equal sixty. Two hundred times forty percent equals eighty, not sixty.

Takeaway: Compare dose times fraction, not percentages alone.

Case sources: [1] [2]

Case 3

A patient has taken a stable pregabalin dose for neuropathic pain. Creatinine clearance falls after an acute illness, and new drowsiness appears despite unchanged dosing. Which exposure change should the clinician consider first?

Show answer and explanations for case 3

  1. A. Faster renal elimination lowers exposure (Why this does not fit)

    Lower renal function generally reduces pregabalin clearance. Drug can remain longer rather than leave faster.

  2. B. New hepatic metabolism lowers exposure (Why this does not fit)

    Pregabalin is predominantly eliminated unchanged in urine. No supplied finding establishes a compensating hepatic clearance pathway.

  3. C. Slower renal elimination increases exposure (Best answer)

    The patient’s capacity to remove pregabalin declined. Slower removal can increase exposure during repeated dosing.

  4. D. Saturated oral absorption prevents accumulation (Why this does not fit)

    It describes entry into the circulation. Predictable entry cannot compensate for slower renal removal.

Takeaway: An unchanged dose can become a different exposure when clearance changes.

Case sources: [2] [7]

Case 4

In a trafficking experiment, researchers compare neurons with an intact alpha-2-delta binding site and neurons with a binding-disrupting mutation. Baseline calcium currents and viability are similar. After sustained gabapentin exposure, surface channel abundance and evoked current fall only in the intact group; total cellular channel protein remains similar in both. Which interpretation best fits the localization and mutation results?

Show answer and explanations for case 4

  1. A. Binding-dependent channel redistribution, without evidence that total synthesis was suppressed (Best answer)

    The change is in channel location or delivery rather than demonstrated loss of all cellular protein. The drug effect requires the intact binding-site context in this preparation. The findings support binding-dependent trafficking effects, not a proved global synthesis shutdown.

  2. B. Binding-independent channel redistribution, without evidence that total synthesis was suppressed (Why this does not fit)

    Redistribution is compatible with lower surface abundance and preserved total protein. The drug-associated change disappears in the binding-disrupted group.

  3. C. Binding-dependent suppression of total synthesis, with a corresponding loss of cellular protein (Why this does not fit)

    Only the intact group shows the measured drug effect. Total cellular channel protein remains similar despite the surface reduction.

  4. D. Binding-independent suppression of total synthesis, with a corresponding loss of cellular protein (Why this does not fit)

    The effect differs by binding-site status and by surface versus total measurement. It ignores both the absent mutant effect and the preserved total protein.

Takeaway: Use the location measurement and the perturbation control as separate constraints.

Case sources: [1] [3]

Case 5

A laboratory finds unchanged resting extracellular glutamate after pregabalin exposure in a neuronal preparation. A colleague concludes that the drug cannot alter transmitter release. The team wants to test that conclusion rather than infer a clinical pain response from the resting measurement. Which additional comparison most directly addresses the unresolved release question?

Show answer and explanations for case 5

  1. A. Measure glutamate release during a standardized depolarizing stimulus, comparing drug and vehicle conditions (Best answer)

    The original measurement assessed resting conditions rather than stimulus-evoked release. It can reveal a change in evoked release even when resting extracellular glutamate is unchanged. The measured release response does not determine an individual patient analgesic effect.

  2. B. Repeat the resting extracellular glutamate measurement in a second unstimulated sample (Why this does not fit)

    It can assess reproducibility of the resting measurement. It still does not test transmitter release during stimulation.

  3. C. Measure total intracellular glutamate in the treated and untreated preparations (Why this does not fit)

    It assesses the transmitter pool rather than the amount released during a specified stimulus. A preserved pool does not establish unchanged stimulus-evoked release.

  4. D. Measure total cellular calcium-channel protein in the treated and untreated preparations (Why this does not fit)

    It can examine the total channel-protein pool. It does not directly measure glutamate release during neuronal stimulation.

Takeaway: A normal resting measurement does not answer what happens during a stimulus.

Case sources: [6]

Case 6

A patient whose focal seizures have been controlled with immediate-release gabapentin 600 mg three times daily develops stable chronic renal impairment with creatinine clearance 45 mL/min. The clinician will individualize the transition while maintaining seizure-treatment continuity. Which listed replacement plan respects both the existing formulation indication and the label renal range?

Show answer and explanations for case 6

  1. A. Immediate-release gabapentin, 400 mg twice daily (Best answer)

    Immediate-release gabapentin preserves it; GRALISE is a different PHN product. At CrCl above thirty to fifty-nine, the immediate-release label uses four hundred to fourteen hundred milligrams daily in two divided doses. It fits those constraints but still requires an individualized transition and seizure follow-up.

  2. B. Immediate-release gabapentin, 600 mg three times daily (Why this does not fit)

    The immediate-release formulation remains appropriate to the established indication. Eighteen hundred milligrams daily exceeds the stated label range for this renal category.

  3. C. GRALISE, 1200 mg once daily with the evening meal (Why this does not fit)

    CrCl forty-five is within a renal range where GRALISE has labeled PHN regimens. GRALISE is not interchangeable with the immediate-release seizure regimen and is labeled for PHN.

  4. D. GRALISE, 1800 mg once daily with the evening meal (Why this does not fit)

    No, correct GRALISE administration does not create formulation equivalence. Maintaining appropriate therapy for the existing focal-seizure indication.

Takeaway: Product identity and renal exposure limits must both fit the plan.

Case sources: [1] [13]

Case 7

A pharmacokinetic teaching simulation for a renally cleared oral drug reports dose 100 units, bioavailability 0.60 and clearance 10 units/time. In a second run the dose is 200 units, bioavailability 0.40 and clearance 5 units/time. Volume of distribution is unchanged. For this model, total exposure is proportional to bioavailability times dose divided by clearance. Which exposure ratio and explanation are correct? Use the stated model values to calculate the exposure ratio; clinical dosing requires patient-specific assessment.

Show answer and explanations for case 7

  1. A. 1.33-fold, because only the amount absorbed changes (Why this does not fit)

    It measures the increase in absorbed amount. Clearance also falls from ten to five, doubling persistence for a given absorbed input.

  2. B. 0.67-fold, because the absorbed fraction falls (Why this does not fit)

    Both the administered dose and clearance changed. Compare fraction times dose divided by clearance in each run.

  3. C. 4.00-fold, because the administered dose doubles and clearance halves (Why this does not fit)

    Bioavailability falls from 0.60 to 0.40. Eighty model units enter, not one hundred twenty.

  4. D. 2.67-fold, because absorbed amount rises and clearance falls (Best answer)

    They are sixty divided by ten and eighty divided by five, giving six and sixteen. Sixteen divided by six is approximately 2.67. The larger absorbed amount and slower removal outweigh that fractional decline.

Takeaway: Calculate entry and removal separately before combining their effects.

Case sources: [1] [2] [7]

Case 8

A patient on unchanged immediate-release pregabalin begins taking each dose with a substantial meal rather than fasting. During the same week, renal assessment confirms a fall in creatinine clearance; no other medication or formulation changes occur. Compared with the previous fasting, preserved-clearance regimen, which peak-timing and total-exposure pattern is most consistent with these two changes?

Show answer and explanations for case 8

  1. A. A later absorption peak and higher total exposure (Best answer)

    Food delays pregabalin peak timing without a clinically meaningful loss of total absorption. Reduced renal clearance slows drug removal. Peak timing describes absorption rate, whereas total exposure also depends on elimination.

  2. B. A later absorption peak and lower total exposure (Why this does not fit)

    A later absorption peak fits taking pregabalin with food. Lower total exposure is not the expected consequence of the documented renal decline with unchanged input.

  3. C. An earlier absorption peak and higher total exposure (Why this does not fit)

    Reduced renal clearance can increase total exposure. Food delays rather than accelerates the pregabalin absorption peak.

  4. D. An earlier absorption peak and lower total exposure (Why this does not fit)

    It predicts a later rather than earlier peak. It predicts greater persistence rather than lower exposure for the unchanged absorbed input.

Takeaway: Predict absorption rate and elimination effects separately before combining them.

Case sources: [2] [7]

Case 9

A patient with postherpetic neuralgia has taken gabapentin 600 mg three times daily without recent missed doses. After several days of poor intake, estimated creatinine clearance falls from 82 to 22 mL/min. New somnolence, unsteady gait and multifocal myoclonus appear. Glucose, sodium and temperature are normal; there is no new focal deficit. The bottle confirms immediate-release gabapentin. Which proposed regimen change best addresses the suspected medication contribution?

Show answer and explanations for case 9

  1. A. Reduce total daily gabapentin exposure using the current renal assessment (Best answer)

    Renal clearance declined substantially. The same repeated input can accumulate, so review a lower-exposure renal-adjusted regimen while assessing the new symptoms.

  2. B. Keep the same daily total but divide it into more frequent doses (Why this does not fit)

    They can alter the timing and size of peaks. Reduced renal removal can still cause excessive total exposure.

  3. C. Substitute the same daily milligrams of GRALISE (Why this does not fit)

    No, GRALISE is not interchangeable with immediate-release gabapentin. GRALISE should not be used at creatinine clearance below thirty.

  4. D. Substitute a normal-renal-function pregabalin regimen (Why this does not fit)

    Both depend substantially on renal clearance. Pregabalin also requires a regimen appropriate to the current renal function.

Takeaway: Change the exposure plan when removal changes; redistribution of the same input is not the same as renal adjustment.

Case sources: [1] [2] [13]

Case 10

An adult with longstanding diabetes has bilateral burning feet, distal sensory loss and reduced ankle reflexes without a prior zoster episode. Creatinine clearance is stably 45 mL/min. A pregabalin renal table maps normal-function daily reference totals of 150, 300, 450 and 600 mg to 75, 150, 225 and 300 mg/day in this renal range. Which mapped daily total corresponds to the US-label upper reference for the described pain condition?

Show answer and explanations for case 10

  1. A. 75 mg/day (Why this does not fit)

    It maps from one hundred fifty milligrams daily. The question asks for the upper diabetic-neuropathic-pain reference, not its usual initial total.

  2. B. 150 mg/day (Best answer)

    The distal symmetric diabetic sensory findings support diabetic peripheral neuropathic pain. It is three hundred milligrams daily. It maps three hundred to one hundred fifty milligrams daily.

  3. C. 225 mg/day (Why this does not fit)

    It corresponds to four hundred fifty milligrams daily with normal renal function. The DPN upper reference is three hundred rather than four hundred fifty.

  4. D. 300 mg/day (Why this does not fit)

    It maps from six hundred milligrams daily. The DPN indication does not use the six-hundred-milligram upper reference.

Takeaway: Derive the condition-specific reference before applying the renal mapping.

Case sources: [2]

Case 11

A clinician is selecting an oral option for painful diabetic polyneuropathy in a patient with established cirrhosis and stable creatinine clearance 45 mL/min. The patient is not taking opioids or other sedatives. Which listed medication and daily upper reference is consistent with both the hepatic precautions and the indication-specific renal guidance, before further adjustment for individual tolerability?

Show answer and explanations for case 11

  1. A. Duloxetine, 30 mg/day (Why this does not fit)

    No, its label advises avoiding use in chronic liver disease or cirrhosis. The established cirrhosis remains relevant regardless of this lower dose.

  2. B. Pregabalin, 300 mg/day (Why this does not fit)

    Pregabalin does not depend on extensive hepatic metabolism. The normal-function DPN upper reference of three hundred maps to one hundred fifty daily at CrCl forty-five.

  3. C. Pregabalin, 150 mg/day (Best answer)

    Duloxetine should be avoided in cirrhosis, whereas pregabalin is mainly renally eliminated. The DPN normal-function reference of three hundred maps to one hundred fifty daily in this renal category. No, the actual regimen still requires titration and assessment of benefit and harm.

  4. D. Duloxetine, 60 mg/day (Why this does not fit)

    Diabetic peripheral neuropathic pain is a labeled indication. The label advises avoiding duloxetine in cirrhosis.

Takeaway: A different elimination route can solve one constraint while leaving another dose adjustment necessary.

Case sources: [2] [15]

Case 12

A teaching simulation isolates two routes of removal for a dialyzable drug. Both compartments begin with 100 units and receive no further input. Compartment A has a six-hour elimination half-life; at hour six a modeled extracorporeal event removes half of the amount then present. Compartment B has a twelve-hour half-life and no extracorporeal event. Ordinary first-order elimination continues in both. At hour twelve, what amounts remain? The instantaneous removal event is a mathematical simplification, not a dialysis prescription.

Show answer and explanations for case 12

  1. A. A: 25 units; B: 50 units (Why this does not fit)

    Without the extra event, two half-lives would leave twenty-five in A and one would leave fifty in B. The modeled event halves the amount remaining in A again.

  2. B. A: 12.5 units; B: 50 units (Best answer)

    It would leave twenty-five units in A and fifty in B. It multiplies the remaining trajectory by one half, leaving twelve and a half units. It omits continuous extracorporeal kinetics, distribution and subsequent dosing.

  3. C. A: 12.5 units; B: 25 units (Why this does not fit)

    Twelve and a half correctly accounts for both processes in A. Only one twelve-hour half-life has elapsed for B.

  4. D. A: 50 units; B: 50 units (Why this does not fit)

    The modeled extracorporeal event would do so. Two periods of ordinary elimination also occur.

Takeaway: Intermittent removal adds to the ordinary elimination trajectory rather than replacing it.

Case sources: [2] [7]

Case 13

A patient reports less benefit after adding an aluminum-magnesium antacid at the same time as immediate-release gabapentin. The gabapentin dose has not changed. Creatinine clearance has also fallen from 80 to 35 mL/min during a recent illness. No drug concentrations are available. What net exposure direction is established by these facts alone?

Show answer and explanations for case 13

  1. A. Lower than before (Why this does not fit)

    Concurrent aluminum-magnesium antacid can reduce gabapentin absorption. Reduced renal clearance can increase persistence, so net exposure is not established.

  2. B. Higher than before (Why this does not fit)

    It tends to increase exposure for a given absorbed input. The concurrent antacid can reduce the amount absorbed.

  3. C. Direction not determined (Best answer)

    It can decrease gabapentin bioavailability when taken together. It can slow elimination and increase persistence. The net exposure change is uncertain, so symptom report alone does not justify escalation.

  4. D. Unchanged from before (Why this does not fit)

    No, the individual exposure changes have not been measured. Two opposing effects need not be equal.

Takeaway: Opposing changes in entry and removal are not automatically equal or self-correcting.

Case sources: [1]

Case 14

Patient A has persistent burning and brush-evoked pain confined to the thoracic dermatome affected by shingles three months earlier. Patient B has years of diabetes with symmetric distal burning, reduced vibration and ankle reflexes, without shingles. For the pain conditions described, which US approval comparison correctly distinguishes immediate-release gabapentin from pregabalin?

Show answer and explanations for case 14

  1. A. A: both products; B: pregabalin only (Best answer)

    It identifies postherpetic neuralgia, a labeled indication for both products. It identifies diabetic peripheral neuropathic pain, a US pregabalin indication but not an immediate-release gabapentin indication. No, approval and evidence-supported off-label use are separate questions.

  2. B. A: gabapentin only; B: pregabalin only (Why this does not fit)

    Pregabalin alone has the US DPN pain indication among these two products. Pregabalin also has a postherpetic-neuralgia indication.

  3. C. A: both products; B: both products (Why this does not fit)

    Both products cover postherpetic neuralgia. Gabapentin use in diabetic neuropathy does not create a US label indication.

  4. D. A: pregabalin only; B: both products (Why this does not fit)

    Immediate-release gabapentin also has a PHN indication. Immediate-release gabapentin does not have the US DPN pain indication.

Takeaway: A correct comparison must classify both clinical patterns and both product labels.

Case sources: [1] [2] [11]

Case 15

A patient taking pregabalin regularly for neuropathic pain runs out for three days. New sweating, insomnia, nausea and anxiety appear; the usual pain and longstanding worry pattern have not noticeably changed. Glucose, bicarbonate and ketones are normal, and the patient is alert with normal breathing. Renal function had been normal when the previous dose was selected, but current creatinine clearance is 25 mL/min. Which combined interpretation best fits the symptom timeline and the exposure expected from restarting the unchanged prior regimen?

Show answer and explanations for case 15

  1. A. An interruption-related syndrome is favored; prior-regimen exposure would now tend to be higher (Best answer)

    New autonomic and sleep symptoms follow missed doses while the previous pain and worry pattern remain similar. Renal clearance is now lower than when the regimen was selected. Exposure would tend to be higher, so any restart or taper needs current clinical and renal assessment.

  2. B. An interruption-related syndrome is favored; prior-regimen exposure would now tend to be unchanged (Why this does not fit)

    The new symptoms after interruption favor a possible withdrawal syndrome. The new renal decline can increase exposure from the same regimen.

  3. C. Recurrence of the original pain or anxiety is favored; prior-regimen exposure would now tend to be higher (Why this does not fit)

    An unchanged regimen can produce greater exposure with reduced clearance. The original pain and worry pattern are similar while new autonomic symptoms followed interruption.

  4. D. Recurrence of the original pain or anxiety is favored; prior-regimen exposure would now tend to be unchanged (Why this does not fit)

    The autonomic and sleep changes appeared after missed doses rather than a described worsening of the original symptoms. Current renal clearance is lower.

Takeaway: The cause of interruption symptoms and the safety of the old regimen are separate judgments.

Case sources: [2] [7]

Case 16

A patient taking prescribed oxycodone and pregabalin becomes difficult to wake with slow respirations after a new renal decline. Emergency personnel support ventilation and administer naloxone. Breathing improves substantially, but somnolence persists. Which conclusion about contributing drug effects and pregabalin elimination is best supported?

Show answer and explanations for case 16

  1. A. An opioid contribution is supported; pregabalin elimination is likely prolonged (Best answer)

    An opioid contribution to the respiratory depression is supported, without proving it was the only cause. Its elimination can be prolonged. Residual pregabalin and other depressant effects can remain and require continued assessment.

  2. B. An opioid contribution is supported; pregabalin elimination is likely unchanged (Why this does not fit)

    An opioid contribution is supported. Pregabalin depends on renal clearance, so elimination may now be prolonged.

  3. C. Only a nonopioid contribution is supported; pregabalin elimination is likely prolonged (Why this does not fit)

    Renal decline can prolong pregabalin elimination. Breathing improved substantially after naloxone.

  4. D. Only a nonopioid contribution is supported; pregabalin elimination is likely unchanged (Why this does not fit)

    Improvement after naloxone supports it. Renal decline can slow pregabalin elimination.

Takeaway: Interpret the antidote response and renal-dependent persistence independently.

Case sources: [2] [8]

Case 17

A patient taking pregabalin for neuropathic pain develops tongue swelling and difficulty breathing shortly after a dose. The patient has taken the medicine regularly for several months and asks whether it must be continued during a one-week taper. Which response best fits this presentation?

Show answer and explanations for case 17

  1. A. Urgent airway assessment, with pregabalin continued during a routine taper (Why this does not fit)

    Urgent airway assessment is appropriate. Suspected pregabalin angioedema requires discontinuation rather than continued exposure solely to follow elective taper advice.

  2. B. Urgent airway assessment, with the suspected pregabalin stopped (Best answer)

    It suggests possible airway-threatening angioedema. Stop the suspected culprit and obtain urgent care rather than delay for an elective taper.

  3. C. Urgent airway assessment, with pregabalin changed to an equivalent liquid dose (Why this does not fit)

    No, a liquid pregabalin dose still exposes the patient to pregabalin. Discontinuing the suspected drug does, alongside urgent care.

  4. D. Urgent airway assessment, with pregabalin continued unless a skin rash appears (Why this does not fit)

    No, tongue swelling and breathing difficulty already raise the concern. Stopping the suspected pregabalin and obtaining urgent care.

Takeaway: Urgent hypersensitivity care overrides a routine elective taper plan.

Case sources: [2]

Case 18

After several weeks of gabapentin, a patient develops fever, enlarged cervical nodes and a rise in aminotransferases, with eosinophilia and no rash. There is no focal source of infection on initial assessment. Which medication-related conclusion is most appropriate?

Show answer and explanations for case 18

  1. A. Continue gabapentin until a rash confirms a multisystem drug reaction (Why this does not fit)

    No, fever or enlarged nodes can be early manifestations without rash. Systemic illness with organ injury and eosinophilia does.

  2. B. Reduce gabapentin as routine dose-related intolerance and reassess after titration (Why this does not fit)

    Fever, lymphadenopathy, eosinophilia and liver injury indicate a systemic process. A potentially serious hypersensitivity reaction requires prompt evaluation.

  3. C. Evaluate a serious gabapentin-associated reaction now, including alternative causes (Best answer)

    Early systemic DRESS manifestations can occur without visible rash. If an alternative cause is not established, the label calls for discontinuing gabapentin.

  4. D. Replace gabapentin with pregabalin before investigating the systemic findings (Why this does not fit)

    It does not identify or manage the possible serious multisystem reaction. Prompt evaluation of the systemic findings and suspected culprit is required.

Takeaway: Investigate systemic warning signs without requiring a rash first.

Case sources: [1]

Case 19

A medication record identifies an immediate-release alpha-2-delta ligand with at least 90 percent oral bioavailability across its therapeutic dose range but omits its name. A patient taking this medicine for neuropathic pain develops ankle edema and weight gain after pioglitazone is added. The ligand dose and renal function remain unchanged. Which drug identification and interaction explanation best fit these findings?

Show answer and explanations for case 19

  1. A. Pregabalin; overlapping fluid-retention effects (Best answer)

    Pregabalin matches that profile rather than immediate-release gabapentin. Pregabalin and thiazolidinediones can have additive effects on peripheral edema and weight gain. The concern does not require inhibition of hepatic pregabalin metabolism.

  2. B. Pregabalin; inhibition of its hepatic CYP-mediated clearance (Why this does not fit)

    Pregabalin fits the high dose-independent bioavailability. Pregabalin undergoes little metabolism and is largely excreted unchanged in urine. Overlapping edema and weight-gain effects warrant assessment.

  3. C. Gabapentin; overlapping fluid-retention effects (Why this does not fit)

    Peripheral edema is a recognized gabapentinoid adverse effect, and pioglitazone can promote fluid retention. The described high dose-independent bioavailability fits pregabalin rather than immediate-release gabapentin.

  4. D. Gabapentin; inhibition of its hepatic CYP-mediated clearance (Why this does not fit)

    Immediate-release gabapentin has dose-dependent bioavailability rather than the stated profile. Gabapentin is renally eliminated without substantial hepatic metabolism.

Takeaway: Identify the drug from its pharmacokinetics, then distinguish overlapping adverse effects from a metabolic interaction.

Case sources: [1] [2]

Case 20

A patient receiving hemodialysis describes an urge to move the legs that starts during rest in the evening and improves while walking. There is no shingles history or persistent dermatomal pain. The clinician reviews whether HORIZANT is an appropriate labeled product for this presentation. Which syndrome and dialysis-related label conclusion fit the supplied findings?

Show answer and explanations for case 20

  1. A. Restless legs pattern; HORIZANT is not recommended for that indication on hemodialysis (Best answer)

    Rest-related evening symptoms relieved by movement support a restless legs pattern. HORIZANT is not recommended for RLS in patients on hemodialysis. It belongs to a different indication and cannot be transferred solely because the renal setting matches.

  2. B. Restless legs pattern; HORIZANT can use its postdialysis PHN regimen for this indication (Why this does not fit)

    The symptom timing and movement response support restless legs. The RLS dialysis instruction differs from the PHN instruction.

  3. C. Postherpetic neuralgia pattern; HORIZANT can use its labeled PHN dialysis regimen (Why this does not fit)

    HORIZANT has PHN-specific dialysis instructions. The described pattern lacks a post-zoster dermatomal pain syndrome.

  4. D. Postherpetic neuralgia pattern; HORIZANT is not recommended for PHN on hemodialysis (Why this does not fit)

    The evening rest-related urge relieved by movement supports restless legs rather than PHN. The dialysis not-recommended statement applies to RLS, while PHN has separate dosing instructions.

Takeaway: The product name and kidney setting do not replace identifying the actual indication.

Case sources: [14]

Case 21

In PRECISE, the eight-week adjusted pregabalin-minus-placebo difference in sciatica leg-pain score was 0.5 points with 95 percent confidence interval -0.2 to 1.2; lower scores are better. The analysis plan used a 1.5-point between-group benefit as its planning target, not a universally validated minimum important difference. Which two conclusions follow from this interval?

Show answer and explanations for case 21

  1. A. Superiority is not established; the planned 1.5-point benefit is excluded by this interval (Best answer)

    It is zero, which lies inside the interval. A one-and-a-half-point pregabalin benefit would be minus 1.5, outside the interval. It avoids both a superiority claim and exact equivalence.

  2. B. Superiority is not established; the planned 1.5-point benefit remains inside this interval (Why this does not fit)

    The interval includes zero, so superiority is not established. Minus 1.5 lies below the lower bound of minus 0.2.

  3. C. Superiority is established; the planned 1.5-point benefit is excluded by this interval (Why this does not fit)

    The planned benefit lies outside the reported interval. The interval crosses the no-difference value of zero.

  4. D. Superiority is established; the planned 1.5-point benefit remains inside this interval (Why this does not fit)

    It prevents a statistically established superiority conclusion from this interval. It does not reach minus 1.5.

Takeaway: The null and a prespecified benefit target answer separate questions.

Case sources: [10] [16]

Case 22

In the Atkinson trial, adults with chronic low back pain received gabapentin or placebo for 12 weeks. Pain fell by about 30 percent in both groups, and the reported between-group comparison had P=.423. A current patient has longstanding diabetes, bilateral burning feet, reduced distal sensation and ankle reflexes, without back pain. Which interpretation correctly combines the randomized result with direct applicability to this patient?

Show answer and explanations for case 22

  1. A. A gabapentin benefit was established; the trial directly studied this patient pattern (Why this does not fit)

    It does not establish a between-group gabapentin benefit. The current distal diabetic neuropathy pattern differs from the chronic-low-back-pain population.

  2. B. A gabapentin benefit was not established; the trial directly studied this patient pattern (Why this does not fit)

    A gabapentin benefit was not demonstrated over placebo in that trial. The current pain pattern is diabetic peripheral neuropathic pain rather than chronic low back pain.

  3. C. A gabapentin benefit was not established; condition-matched evidence is needed for this patient pattern (Best answer)

    The control group improved similarly and the between-group result did not establish benefit. The patient has a different neuropathic-pain condition with its own evidence. Neither within-arm improvement nor a negative trial in another condition supplies a universal efficacy conclusion.

  4. D. A gabapentin benefit was established; condition-matched evidence is needed for this patient pattern (Why this does not fit)

    The diabetic neuropathy pattern requires its own condition-matched evidence. Improvement in both arms did not establish a randomized gabapentin benefit.

Takeaway: Interpret the randomized comparison and the population match as separate questions.

Case sources: [9] [11]

Case 23

A trial reports the following neuropathic-pain outcomes. The adjusted drug-minus-placebo pain difference is -0.8 points with 95 percent CI -1.2 to-0.4; lower scores are better. The safety report gives 34 versus 20 adverse events among 100 participants per group, but does not identify the number of unique participants with a defined harm. Which summary is supported?

Show answer and explanations for case 23

  1. A. A lower mean pain score is established; a patient-level NNH cannot be calculated from these safety totals (Best answer)

    It lies wholly below zero, supporting a lower mean pain score in the drug group. The counts do not identify unique participants experiencing a defined harm. It would require the reciprocal of an absolute patient-risk increase for a specified harm and interval.

  2. B. A lower mean pain score is established; the event totals are sufficient for a patient-level NNH (Why this does not fit)

    A lower mean pain score is supported by the interval below zero. An event total is not the count of people experiencing a defined event.

  3. C. A lower mean pain score is not established; a patient-level NNH cannot be calculated from these safety totals (Why this does not fit)

    Unique-patient risks needed for NNH are not supplied. The entire interval is below zero rather than crossing it.

  4. D. A lower mean pain score is not established; the event totals are sufficient for a patient-level NNH (Why this does not fit)

    The confidence interval is wholly negative on the specified scale. Repeated events in the same participant prevent inferring unique-patient risks.

Takeaway: A measured benefit and a calculable harm risk require different evidence.

Case sources: [10]

Case 24

A patient with painful diabetic polyneuropathy has had no meaningful benefit from an adequate trial of gabapentin at the maximum tolerated renal-adjusted regimen; further escalation causes dizziness. A prior amitriptyline trial for another problem caused urinary retention requiring catheterization, and the patient wishes to avoid re-exposure. Renal and hepatic function are otherwise suitable for the listed alternatives. Which drug is the best-supported next trial under the AAN different-class strategy?

Show answer and explanations for case 24

  1. A. Amitriptyline (Why this does not fit)

    Yes, TCAs are a different guideline-supported class for painful diabetic polyneuropathy. The patient had serious urinary retention with this medicine and wishes to avoid re-exposure.

  2. B. Pregabalin (Why this does not fit)

    It would avoid re-exposure to the prior TCA. Pregabalin remains in the same gabapentinoid class as the failed therapy.

  3. C. Oxycodone (Why this does not fit)

    No, it must be an effective class recommended for this condition. The AAN guideline recommends against opioids for painful diabetic polyneuropathy.

  4. D. Duloxetine (Best answer)

    The guideline supports trying a different effective class. The previous severe TCA-related urinary retention argues against amitriptyline re-exposure. It is an SNRI in a different effective class, subject to its own precautions and an individualized transition.

Takeaway: A different drug name is not enough; class and patient-specific harms both matter.

Case sources: [11] [15] [17]

Case 25

An adult with established fibromyalgia and generalized anxiety disorder is discussing medication choices with a US clinician. The patient would prefer one medicine if appropriate, and asks which listed product has US-label indications for both diagnosed conditions. Renal and hepatic function are preserved, and no interacting drugs are reported. Which product meets that regulatory description, without implying it will be the best choice for every patient?

Show answer and explanations for case 25

  1. A. Pregabalin (Why this does not fit)

    Fibromyalgia has that indication. Generalized anxiety disorder is not a US LYRICA indication, even though it is authorized in Europe.

  2. B. Duloxetine (Best answer)

    Pregabalin and duloxetine include fibromyalgia. Duloxetine also includes generalized anxiety disorder in adults. It does not replace individualized benefit, tolerability and safety assessment.

  3. C. Venlafaxine extended release (Why this does not fit)

    Generalized anxiety disorder has that indication. Fibromyalgia is not one of its labeled indications.

  4. D. Immediate-release gabapentin (Why this does not fit)

    It is a related alpha-2-delta ligand used for selected neuropathic conditions. Its US label includes neither fibromyalgia nor generalized anxiety disorder.

Takeaway: A single-medicine label match requires checking both conditions, not just one.

Case sources: [1] [2] [12] [15] [18]

Case 26

After several months of prescribed pregabalin, a patient experiences insomnia and sweating during an unintended interruption. The patient reports taking only the agreed dose, no compulsive use, no loss of control and no continued use despite recognized harm. Which conclusion is justified by these facts?

Show answer and explanations for case 26

  1. A. Physical dependence is supported; a substance use disorder is also established (Why this does not fit)

    Physical dependence may contribute to the symptoms. A substance use disorder requires a broader behavioral assessment than withdrawal alone.

  2. B. Physical dependence is unsupported; a substance use disorder is established (Why this does not fit)

    An interruption syndrome can occur after regular prescribed use. A substance use disorder is not established.

  3. C. Physical dependence is unsupported; a substance use disorder is not established (Why this does not fit)

    The supplied facts do not establish a substance use disorder. Symptoms following interruption remain compatible with physiologic adaptation.

  4. D. Physical dependence is supported; a substance use disorder is not established (Best answer)

    They can reflect physical dependence after regular exposure. Withdrawal alone does not establish the loss-of-control or harmful-use pattern of a substance use disorder.

Takeaway: Physiologic adaptation and a behavioral use disorder are related but distinct assessments.

Case sources: [2]

Case 27

Four adults with normal renal function have completed four weeks of pregabalin 300 mg/day and still report troublesome pain. Which follow-up profile meets the US-label indication and tolerability conditions for considering a higher pregabalin dose? This asks about eligibility for consideration, not a mandatory escalation.

Show answer and explanations for case 27

  1. A. Postherpetic neuralgia; daily dizziness with two near-falls (Why this does not fit)

    PHN can allow consideration of higher dosing after an adequate trial. Daily dizziness and near-falls indicate poor tolerability.

  2. B. Diabetic peripheral neuropathic pain; no limiting adverse effects (Why this does not fit)

    The regimen is tolerated. The US DPN normal-function maximum is three hundred milligrams daily.

  3. C. Postherpetic neuralgia; no limiting adverse effects (Best answer)

    PHN can permit consideration of higher dosing after persistent pain on an adequate three-hundred-milligram trial. There are no limiting adverse effects. Whether the possible benefit justifies escalation still requires individualized discussion.

  4. D. Diabetic peripheral neuropathic pain; daily dizziness with two near-falls (Why this does not fit)

    The DPN upper reference is already reached. Daily dizziness and near-falls argue against escalation.

Takeaway: Dose-range eligibility depends on both the indication and the actual tolerated course.

Case sources: [2]

Case 28

A pharmacokinetic model compares the same 100-unit intravenous and oral doses in two periods, with linear elimination within each period. In period 1, IV AUC is 100 and oral AUC is 60. In period 2, IV AUC is 200 and oral AUC is 80. Use F=oral AUC/IV AUC for these equal doses and clearance=IV dose/IV AUC. Which combined change is supported? This constructed IV/oral exercise is not a clinical pregabalin dosing protocol.

Show answer and explanations for case 28

  1. A. Bioavailability rises; clearance rises (Why this does not fit)

    Eighty divided by two hundred is 0.40, lower than 0.60. It falls from 1 to 0.5 rather than rising.

  2. B. Bioavailability rises; clearance falls (Why this does not fit)

    Clearance falls because the same IV dose produces twice the IVexposure. The oral AUC must be compared with the independently changed IVreference.

  3. C. Bioavailability falls; clearance rises (Why this does not fit)

    Ffalls from 0.60 to 0.40. A larger IV AUC from the same dose corresponds to lower, not higher, clearance.

  4. D. Bioavailability falls; clearance falls (Best answer)

    They are 60/100=0.60 and 80/200=0.40. They are 100/100=1 and 100/200=0.5 in the model units. Reduced clearance can increase exposure enough to outweigh lower bioavailability.

Takeaway: Use an IV reference to separate a change in absorbed fraction from a change in removal.

Case sources: [1] [2] [7]

Sources

  1. NEURONTIN prescribing information, Viatris / DailyMed (2025-04)

    Immediate-release indications, absorption, renal elimination and dosage, interactions, discontinuation and serious warnings; the label states clinical mechanism is incompletely established.

  2. LYRICA prescribing information, Viatris / DailyMed (2025-04)

    Indication-specific dose reference, renal mapping, food and clearance, serious respiratory and hypersensitivity warnings; not a universal class dosing table.

  3. Hendrich et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin (2008)

    Primary experimental trafficking and binding-disruption results; used as experimental reasoning, not an individual clinical-effect predictor.

  4. Bauer et al. Increased alpha2delta-1 trafficking to presynaptic terminals is inhibited by pregabalin (2009)

    Rat nerve-injury study distinguishes terminal trafficking from DRG expression. Compare terminal trafficking with DRG expression.

  5. Transport of pregabalin in rat intestine and Caco-2 monolayers (1999)

    Experimental transport findings limit a blanket passive-diffusion account of pregabalin absorption in humans.

  6. Quintero et al. Glutamate release modulation by gabapentin and pregabalin in rodent cortical tissue (2011)

    Basal versus stimulus-evoked release and alpha2delta-1 binding-disruption controls; experimental effects remain distinguished from patient outcomes.

  7. Randinitis et al. Pharmacokinetics of pregabalin with different renal function (2003)

    Primary single-dose renal-function and hemodialysis study; supports clearance/exposure relationships, not a stand-alone prescribing algorithm.

  8. FDA: Serious breathing problems with gabapentin and pregabalin (2019-12-19)

    Respiratory risk with CNS depressants, respiratory impairment and older age; clinical monitoring and urgent warning signs, without invented numeric risk scores.

  9. Atkinson et al. Randomized controlled trial of gabapentin for chronic low back pain (2016)

    Primary 12-week placebo-controlled trial: interpretation of within-group improvement and lack of demonstrated between-group benefit in the studied back-pain population.

  10. Mathieson et al. Trial of Pregabalin for Acute and Chronic Sciatica (2017)

    PRECISE primary outcome, confidence interval and adverse-event counts; event totals are not counts of distinct harmed patients. Population-specific interpretation.

  11. AAN: Oral and topical treatment of painful diabetic polyneuropathy, guideline update (2022)

    Effective medication classes, assessment of mood/sleep and patient factors, change to a different effective class after failure or significant adverse effects; opioids are not recommended for PDN.

  12. European Medicines Agency: Lyrica authorization information

    European adult generalized anxiety indication is distinguished from US product approval.

  13. GRALISE prescribing information, Almatica / DailyMed (2026-06)

    PHN formulation is not interchangeable with other gabapentin products; evening-meal administration and renal-use restrictions are product specific.

  14. HORIZANT prescribing information, Azurity / DailyMed (2025-04)

    Gabapentin-enacarbil product, RLS and PHN distinction, noninterchangeability, and indication-specific hemodialysis instructions.

  15. CYMBALTA prescribing information, Eli Lilly / DailyMed (2023-08)

    US indications for adult GAD, DPN pain and fibromyalgia; avoid use in chronic liver disease or cirrhosis. Label updatedJuly2025; dose proposals remain individualized.

  16. PRECISE: pregabalin in addition to usual care, a priori statistical analysis plan (2016)

    Prespecified1.5/10between-group leg-pain effect used in sample-size planning and analysis. This is a trial planning target, not proof of a universal minimum important difference.

  17. Amitriptyline hydrochloride prescribing information, Accord / DailyMed

    Atropine-like effects and caution with a history of urinary retention; used with the AAN class guidance to assess prior serious intolerance, not to claim a neuropathy label indication.

  18. EFFEXOR XR prescribing information, Wyeth / DailyMed (2022-08)

    Adult US indications include GAD but not fibromyalgia; comparison of label scope does not establish relative efficacy.

Return to lesson title

Search Bone Wizardry

Quick links
↑ ↓ Navigate Enter Open Esc CloseBrowse the library ↗